Literature DB >> 23675690

Alterations of histone H1 phosphorylation during bladder carcinogenesis.

Kelly H Telu1, Besma Abbaoui, Jennifer M Thomas-Ahner, Debra L Zynger, Steven K Clinton, Michael A Freitas, Amir Mortazavi.   

Abstract

There is a crucial need for development of prognostic and predictive biomarkers in human bladder carcinogenesis in order to personalize preventive and therapeutic strategies and improve outcomes. Epigenetic alterations, such as histone modifications, are implicated in the genetic dysregulation that is fundamental to carcinogenesis. Here we focus on profiling the histone modifications during the progression of bladder cancer. Histones were extracted from normal human bladder epithelial cells, an immortalized human bladder epithelial cell line (hTERT), and four human bladder cancer cell lines (RT4, J82, T24, and UMUC3) ranging from superficial low-grade to invasive high-grade cancers. Liquid chromatography-mass spectrometry (LC-MS) profiling revealed a statistically significant increase in phosphorylation of H1 linker histones from normal human bladder epithelial cells to low-grade superficial to high-grade invasive bladder cancer cells. This finding was further validated by immunohistochemical staining of the normal epithelium and transitional cell cancer from human bladders. Cell cycle analysis of histone H1 phosphorylation by Western blotting showed an increase of phosphorylation from G0/G1 phase to M phase, again supporting this as a proliferative marker. Changes in histone H1 phosphorylation status may further clarify epigenetic changes during bladder carcinogenesis and provide diagnostic and prognostic biomarkers or targets for future therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23675690      PMCID: PMC3743963          DOI: 10.1021/pr400143x

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  39 in total

1.  Liquid chromatography mass spectrometry profiling of histones.

Authors:  Xiaodan Su; Naduparambil K Jacob; Ravindra Amunugama; David M Lucas; Amy R Knapp; Chen Ren; Melanie E Davis; Guido Marcucci; Mark R Parthun; John C Byrd; Richard Fishel; Michael A Freitas
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-01-07       Impact factor: 3.205

2.  Mass spectrometric mapping of linker histone H1 variants reveals multiple acetylations, methylations, and phosphorylation as well as differences between cell culture and tissue.

Authors:  Jacek R Wisniewski; Alexandre Zougman; Sonja Krüger; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2006-10-15       Impact factor: 5.911

3.  H1.X with different properties from other linker histones is required for mitotic progression.

Authors:  Hideaki Takata; Sachihiro Matsunaga; Akihiro Morimoto; Rika Ono-Maniwa; Susumu Uchiyama; Kiichi Fukui
Journal:  FEBS Lett       Date:  2007-07-10       Impact factor: 4.124

Review 4.  Histone H1 and its isoforms: contribution to chromatin structure and function.

Authors:  Nicole Happel; Detlef Doenecke
Journal:  Gene       Date:  2008-11-14       Impact factor: 3.688

5.  Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.

Authors:  Vitaly Margulis; Shahrokh F Shariat; Raheela Ashfaq; Arthur I Sagalowsky; Yair Lotan
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

Review 6.  Epigenetic biomarkers in urothelial bladder cancer.

Authors:  Wun-Jae Kim; Yong-June Kim
Journal:  Expert Rev Mol Diagn       Date:  2009-04       Impact factor: 5.225

7.  Feasibility of immunocytochemical detection of tumor markers (XIAP, phosphohistone H1 and p63) in FNA cellblock samples from head and neck squamous cell carcinoma.

Authors:  M Wu; A Kafanas; L Gan; D S Kohtz; L Zhang; E Genden; D E Burstein
Journal:  Diagn Cytopathol       Date:  2008-11       Impact factor: 1.582

8.  Global histone modifications predict prognosis of resected non small-cell lung cancer.

Authors:  Fabrice Barlési; Giuseppe Giaccone; Marielle I Gallegos-Ruiz; Anderson Loundou; Simone W Span; Pierre Lefesvre; Frank A E Kruyt; Jose Antonio Rodriguez
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

9.  Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence.

Authors:  Wang L Cheung; Roula Albadine; Theresa Chan; R Sharma; George J Netto
Journal:  J Urol       Date:  2009-01-20       Impact factor: 7.450

10.  Global changes in and characterization of specific sites of phosphorylation in mouse and human histone H1 Isoforms upon CDK inhibitor treatment using mass spectrometry.

Authors:  Leesa J Deterding; Maureen K Bunger; Geoffrey C Banks; Kenneth B Tomer; Trevor K Archer
Journal:  J Proteome Res       Date:  2008-04-17       Impact factor: 5.370

View more
  16 in total

1.  Genome distribution of replication-independent histone H1 variants shows H1.0 associated with nucleolar domains and H1X associated with RNA polymerase II-enriched regions.

Authors:  Regina Mayor; Andrea Izquierdo-Bouldstridge; Lluís Millán-Ariño; Alberto Bustillos; Cristina Sampaio; Neus Luque; Albert Jordan
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

2.  Chromatographic efficiency and selectivity in top-down proteomics of histones.

Authors:  Yiyang Zhou; Ximo Zhang; Luca Fornelli; Philip D Compton; Neil Kelleher; Mary J Wirth
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-12-23       Impact factor: 3.205

3.  The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer.

Authors:  Besma Abbaoui; Kelly H Telu; Christopher R Lucas; Jennifer M Thomas-Ahner; Steven J Schwartz; Steven K Clinton; Michael A Freitas; Amir Mortazavi
Journal:  J Proteomics       Date:  2017-01-27       Impact factor: 4.044

4.  Quantitative Mass Spectrometry Reveals that Intact Histone H1 Phosphorylations are Variant Specific and Exhibit Single Molecule Hierarchical Dependence.

Authors:  Yu Chen; Michael E Hoover; Xibei Dang; Alan A Shomo; Xiaoyan Guan; Alan G Marshall; Michael A Freitas; Nicolas L Young
Journal:  Mol Cell Proteomics       Date:  2015-07-24       Impact factor: 5.911

Review 5.  Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention.

Authors:  Besma Abbaoui; Christopher R Lucas; Ken M Riedl; Steven K Clinton; Amir Mortazavi
Journal:  Mol Nutr Food Res       Date:  2018-08-29       Impact factor: 5.914

6.  Histone H1 phosphorylation in breast cancer.

Authors:  Sean W Harshman; Michael E Hoover; Chengsi Huang; Owen E Branson; Sarah B Chaney; Carolyn M Cheney; Thomas J Rosol; Charles L Shapiro; Vicki H Wysocki; Kay Huebner; Michael A Freitas
Journal:  J Proteome Res       Date:  2014-04-07       Impact factor: 4.466

7.  An Appraisal of Proliferation and Apoptotic Markers in Papillary Thyroid Carcinoma: An Automated Analysis.

Authors:  Monika Lamba Saini; Caroline Bouzin; Birgit Weynand; Etienne Marbaix
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

8.  Proteomic profiling identifies specific histone species associated with leukemic and cancer cells.

Authors:  Rajbir Singh; Sean W Harshman; Amy S Ruppert; Amir Mortazavi; David M Lucas; Jennifer M Thomas-Ahner; Steven K Clinton; John C Byrd; Michael A Freitas; Mark R Parthun
Journal:  Clin Proteomics       Date:  2015-08-27       Impact factor: 3.988

9.  Mapping of six somatic linker histone H1 variants in human breast cancer cells uncovers specific features of H1.2.

Authors:  Lluís Millán-Ariño; Abul B M M K Islam; Andrea Izquierdo-Bouldstridge; Regina Mayor; Jean-Michel Terme; Neus Luque; Mónica Sancho; Núria López-Bigas; Albert Jordan
Journal:  Nucleic Acids Res       Date:  2014-01-29       Impact factor: 16.971

10.  Linker histone H1.2 establishes chromatin compaction and gene silencing through recognition of H3K27me3.

Authors:  Jin-Man Kim; Kyunghwan Kim; Vasu Punj; Gangning Liang; Tobias S Ulmer; Wange Lu; Woojin An
Journal:  Sci Rep       Date:  2015-11-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.